Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 6
2020 6
2021 13
2022 15
2023 25
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Tegoprazan to treat gastroesophageal reflux disease.
Mermelstein J, Mermelstein AC, Chait MM. Mermelstein J, et al. Drugs Today (Barc). 2020 Nov;56(11):715-721. doi: 10.1358/dot.2020.56.11.3202811. Drugs Today (Barc). 2020. PMID: 33332479
A highly selective inhibitor of the H+/K+-ATPase, tegoprazan is also safe and effective for nocturnal acid breakthrough (NAB) and motility. Further studies of tegoprazan are warranted to define its potential role in the treatment of acid-related disorders....
A highly selective inhibitor of the H+/K+-ATPase, tegoprazan is also safe and effective for nocturnal acid breakthrough (NAB) and mot …
Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
Lee KJ, Son BK, Kim GH, Jung HK, Jung HY, Chung IK, Sung IK, Kim JI, Kim JH, Lee JS, Kwon JG, Park JH, Huh KC, Park KS, Park MI, Kim N, Lee OY, Jee SR, Lee SK, Youn SJ, Kim SK, Lee ST, Hong SJ, Choi SC, Kim TN, Youn YH, Park HJ, Kang MJ, Park CH, Kim BT, Youn S, Song GS, Rhee PL. Lee KJ, et al. Aliment Pharmacol Ther. 2019 Apr;49(7):864-872. doi: 10.1111/apt.15185. Epub 2019 Mar 6. Aliment Pharmacol Ther. 2019. PMID: 30843245 Free PMC article. Clinical Trial.
RESULTS: The cumulative healing rates at week 8 were 98.9% (91/92), 98.9% (90/91) and 98.9% (87/88) for tegoprazan 50 mg, tegoprazan 100 mg and esomeprazole 40 mg, respectively. Both doses of tegoprazan were non-inferior to esomeprazole 40 mg. The incidence o …
RESULTS: The cumulative healing rates at week 8 were 98.9% (91/92), 98.9% (90/91) and 98.9% (87/88) for tegoprazan 50 mg, tegopraz …
Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.
Yang E, Kim S, Kim B, Kim B, Kim Y, Park SS, Song GS, Yu KS, Jang IJ, Lee S. Yang E, et al. Br J Clin Pharmacol. 2022 Jul;88(7):3288-3296. doi: 10.1111/bcp.15268. Epub 2022 Feb 23. Br J Clin Pharmacol. 2022. PMID: 35146797 Free PMC article. Clinical Trial.
Furthermore, tegoprazan showed no CYP2C19 phenotype dependency in acid suppression. It suggests the potential of tegoprazan, especially in preventing nocturnal acid breakthrough....
Furthermore, tegoprazan showed no CYP2C19 phenotype dependency in acid suppression. It suggests the potential of tegoprazan, e …
Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.
Cho YK, Choi MG, Choi SC, Lee KM, Kim TO, Park SH, Moon JS, Lim YJ, Kang DH, Cheon GJ, Baik GH, Kim KO, Cho KB, Jang JS, Park JJ, Son BK, Jung HK, Kim BW, Kim SK, Lee ST, Cha JM, Kim AR, Kim EJ, Park HW, Song GS. Cho YK, et al. Aliment Pharmacol Ther. 2020 Sep;52(5):789-797. doi: 10.1111/apt.15865. Epub 2020 Jul 23. Aliment Pharmacol Ther. 2020. PMID: 32701188 Free PMC article. Clinical Trial.
RESULTS: In the full analysis set, the cumulative healing rates at week 8 were 94.8% (91/96) for the tegoprazan 50 mg, 95.0% (94/99) for the tegoprazan 100 mg and 95.7% (89/93) for the lansoprazole 30 mg groups. ...In per protocol analysis, 4-week healing rates were …
RESULTS: In the full analysis set, the cumulative healing rates at week 8 were 94.8% (91/96) for the tegoprazan 50 mg, 95.0% (94/99) …
Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial.
Choi YJ, Lee YC, Kim JM, Kim JI, Moon JS, Lim YJ, Baik GH, Son BK, Lee HL, Kim KO, Kim N, Ko KH, Jung HK, Shim KN, Chun HJ, Kim BW, Lee H, Kim JH, Chung H, Kim SG, Jang JY. Choi YJ, et al. Gut Liver. 2022 Jul 15;16(4):535-546. doi: 10.5009/gnl220055. Epub 2022 Jul 6. Gut Liver. 2022. PMID: 35791797 Free PMC article. Clinical Trial.
BACKGROUND/AIMS: We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication. METHODS: A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-bas …
BACKGROUND/AIMS: We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori era …
Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication.
Kwon YH, Jeon SW, Nam SY, Lee DW, Park JH, Bae HJ. Kwon YH, et al. Korean J Intern Med. 2023 Jul;38(4):493-503. doi: 10.3904/kjim.2022.345. Epub 2023 Jun 28. Korean J Intern Med. 2023. PMID: 37369525 Free PMC article.
BACKGROUND/AIMS: Tegoprazan, a novel potassium-competitive acid blocker, has shown rapid action and gastric acid inhibition. In this study, we evaluated the efficacy of a tegoprazan-based, nonbismuth-containing quadruple (concomitant) therapy for the primary eradica …
BACKGROUND/AIMS: Tegoprazan, a novel potassium-competitive acid blocker, has shown rapid action and gastric acid inhibition. In this …
Tegoprazan as a New Remedy for Gastrointestinal Diseases in Comparison with its Therapeutic Predecessors: A Mini-Review.
Anik AH, Proma FA, Saha P, Sarker S. Anik AH, et al. Curr Drug Res Rev. 2023 Apr 28. doi: 10.2174/2589977515666230428140741. Online ahead of print. Curr Drug Res Rev. 2023. PMID: 37132138
A number of studies have compared the effectiveness as well as the safety profile of tegoprazan to PPIs and other P-CABs for the treatment of gastrointestinal diseases. OBJECTIVE: The current review study evaluates the published works of literature related to clinical phar …
A number of studies have compared the effectiveness as well as the safety profile of tegoprazan to PPIs and other P-CABs for the trea …
Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease.
Kim SH, Cho KB, Chun HJ, Lee SW, Kwon JG, Lee DH, Kim SG, Jung HY, Kim JW, Lee JS, Park H, Choi SC, Jee SR, Kim HS, Ko KH, Park SJ, Lee YC, Park SH, Kim AR, Kim EJ, Park HW, Kim BT, Song GS. Kim SH, et al. Aliment Pharmacol Ther. 2021 Aug;54(4):402-411. doi: 10.1111/apt.16477. Epub 2021 Jul 6. Aliment Pharmacol Ther. 2021. PMID: 34227708 Free PMC article. Clinical Trial.
METHODS: In this phase 3, double-blind, placebo-controlled, multicentre study, 324 Korean patients with NERD were randomised into three treatment groups: tegoprazan 50 mg, tegoprazan 100 mg and placebo. These drugs were provided once daily for 4 weeks. ...RESULTS: A …
METHODS: In this phase 3, double-blind, placebo-controlled, multicentre study, 324 Korean patients with NERD were randomised into three trea …
Characterisation of degradation products of tegoprazan by LC-MS and GC-MS.
Guo K, He X, Zhao H, Ma C. Guo K, et al. J Pharm Biomed Anal. 2023 May 10;228:115323. doi: 10.1016/j.jpba.2023.115323. Epub 2023 Mar 4. J Pharm Biomed Anal. 2023. PMID: 36921447
Tegoprazan showed instability in acidic, alkaline, and oxidative conditions. ...Meanwhile, DP-1, DP-2 and DP-3 were successfully synthesized and confirmed by NMR. The degradation pathway of tegoprazan was summarized. To the best of our knowledge, this is the first s …
Tegoprazan showed instability in acidic, alkaline, and oxidative conditions. ...Meanwhile, DP-1, DP-2 and DP-3 were successfully synt …
67 results

Searches related to "tegoprazan"